Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
April 22, 2021 10:53 ET | Source: Amarin Corporation plc Amarin Corporation plc Bedminster, New Jersey, UNITED STATES
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication
1,2,
VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorization for VAZKEPA (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascul